Treace Medical Concepts (TMCI) just wrapped up FY 2025 with Q4 revenue of US$62.5 million and a basic EPS loss of US$0.15, while trailing twelve month figures show revenue of US$212.7 million and a basic EPS loss of US$0.93. The company has seen quarterly revenue move between US$45.1 million and US$68.7 million over the last six reported periods, with basic EPS losses ranging from US$0.01 to US$0.28. This puts the focus squarely on how efficiently that revenue base can eventually support profitability. With the market already aware of the ongoing losses, this set of results is likely to be read through a margins lens, as investors weigh revenue consistency against the effort required to close the gap to breakeven.

See our full analysis for Treace Medical Concepts.

With the numbers on the table, the next step is to see how this latest print lines up with the main stories around TMCI, including what the community expects for growth, profitability and risks over the longer term.

Losses Remain Heavy At TTM Level

• Over the last twelve months, TMCI generated US$212.7 million in revenue but still recorded a net loss of US$59.0 million, with basic EPS at a loss of US$0.93.
• Bears worry that this pattern of losses, which data shows has worsened at about 27.2% a year over five years, lines up with the expectation that the company is not forecast to be profitable within the next three years.
  • That five year loss growth rate and the trailing net loss of US$59.0 million both back up the cautious view that revenue expansion alone has not yet translated into earnings improvement.
  • The fact that analysts still do not project profitability in the near term uses figures like the US$59.0 million TTM loss as support for the bearish concern about how long it could take to reach breakeven.

Treace’s bears point to that US$59.0 million trailing loss as proof that the road to positive EPS may be longer than many expect, and they argue investors should stress test their own assumptions before leaning on any recovery story. 🐻 Treace Medical Concepts Bear Case

Quarterly Losses Narrow Versus Mid Year

• Within FY 2025, net loss moved from US$17.4 million in Q2 to US$16.3 million in Q3 and then US$9.4 million in Q4, with basic EPS losses of US$0.28, US$0.26 and US$0.15 respectively.
• Consensus narrative highlights ongoing cost discipline and a trajectory toward breakeven, and this run from a US$17.4 million loss in Q2 to US$9.4 million in Q4 gives some numerical support while still sitting alongside a full year TTM loss of US$59.0 million.
  • The sequential improvement within 2025 fits the idea that expense control is starting to show up in reported numbers, even though TMCI remained loss making every quarter.
  • At the same time, the trailing EPS loss of US$0.93 keeps the consensus view grounded in the reality that profitability remains a work in progress rather than a near term event.

Low 0.6x P/S Versus Ongoing Losses

• The shares trade on a P/S of 0.6x, well below both the 4.6x peer average and the 2.9x US Medical Equipment industry average, even though TMCI stayed unprofitable over the last twelve months.
• Bullish investors argue this wide P/S gap, combined with revenue growth measured at 2.9% a year, leaves room for upside, but the TTM net loss of US$59.0 million and the view that the company is not expected to be profitable within three years are the main checks on that optimism.
  • The low 0.6x P/S is the key data point supporting the bullish idea that the stock looks inexpensive relative to peers and the wider industry on sales alone.
  • However, the same dataset showing five year loss growth of 27.2% a year and continued red ink challenges the bullish assumption that the current valuation gap will necessarily close without clearer progress on profitability.

Bulls point to that 0.6x P/S as a potential mispricing, while critics highlight the five year loss trend and TTM net loss as a reminder that any recovery story still needs to be earned in the numbers. 🐂 Treace Medical Concepts Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Treace Medical Concepts on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of cautious and optimistic takes feels familiar, it may be a good time to review the numbers yourself and decide where you stand, starting with 1 key reward and 1 important warning sign.

Explore Alternatives

TMCI is still carrying a trailing twelve month net loss of US$59.0 million and five year loss growth of 27.2% a year, with analysts not projecting near term profitability.

If that mix of ongoing losses and uncertainty around the path to breakeven feels uncomfortable, take a few minutes to scan 77 resilient stocks with low risk scores that aim to prioritise more resilient financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.